High Risk Prostate Cancer Clinical Trial
Official title:
PROspective Multicenter Observational Study on Elective Pelvic Nodes (PRO-EPI) Irradiation in Patients With Intermediate/High/Very High Risk Prostate Cancer
The general aim of the study is to describe the use of elective pelvic node irradiation (ENI)
in Italy, in patients with intermediate/high/very high-risk prostate cancer patients
submitted to adjuvant or radical Radiation Therapy (RT) with or without concomitant Androgen
Deprivation hormone Therapy (ADT).
The study aims at the definition of survival, toxicity and QoL data in a representative
sample of intermediate, high and very high risk prostate cancer patients consecutively
recruited in Italian Radiation Oncology Center over two years.
Clinical features and outcomes of the patients included in the study will be assessed as
better detailed in the following lines:
1. To define the diffusion of the practice of treating pelvic lymph-nodes in patients
affected by intermediate/high/very high risk non-metastatic prostate cancer (PCa) among
Italian Radiation Oncology Centers, submitted to radical or post-operative radiotherapy;
2. To define the diffusion of the different radiotherapy techniques used to treat pelvic
nodes and the other features of the radiation treatment;
3. To register prospectively biochemical and clinical failure, prostate cancer deaths and
deaths for any cause in the population studied;
4. To register prospectively the toxicity due to radiotherapy and androgen deprivation
therapy in patients treated with pelvic nodes radiotherapy;
5. To compare clinical outcomes and toxicities observed in the different clinical and
therapeutic subgroups with the corresponding historical data relative to PCa patients
treated with radiotherapy with or without elective pelvic nodal irradiation, already
available in the existing Italian Society of Radiation Oncology databases;
6. To exploit the collected data to define the need and the features of a prospective
randomized trial evaluating the efficacy of elective pelvic nodal irradiation in
patients with intermediate/high/very high risk non-metastatic prostate cancer.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05917860 -
Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06117059 -
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
|
N/A | |
Completed |
NCT01379872 -
Assessment of New Radiation Oncology Technologies and Treatments
|
N/A | |
Recruiting |
NCT03740191 -
Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer
|
N/A | |
Completed |
NCT02028988 -
Enzalutamide + External Beam Rt For Prostate
|
Phase 2 | |
Active, not recruiting |
NCT03815942 -
VAccination in Early and ADvanced Prostate caNCEr
|
Phase 1/Phase 2 |